Stock Analiz

Pharming Group N.V. PHAR

Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026

$12.60Market cap $890M
Open the interactive analysis →

Pharming Group N.V. (PHAR) is a healthcare company listed in the US with a market value of about $890M. In the twelve months to September 30, 2026 it had revenue of $387M and net income of $24M, a net margin of 6.3%.

Its overall Stock Analiz score is 2.2 out of 5 (weak). The strongest part is future growth (5/5); the weakest is value (0/5).

Key numbers: a P/E of 39.4, a price to free cash flow of 25.8, 5-year revenue growth of 12% a year, a 5-year average ROIC of 3%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 65% below the current price.

About Pharming Group

Pharming Group is listed in the US and classified in biotechnology: pharmaceutical preparations. Revenue went from $189M in 2019 to $376M in 2025, growth of about 12.1% a year. It was profitable in 5 of the last 7 years in our data.

Score: 2.2 / 5

Value0/5
Future growth5/5
Track record1/5
Financial health4/5
Shareholder returns1/5

Checks passed

  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • 3-year free cash flow growth above 10% a year
  • Strong R&D investment or growth above 20%
  • 5-year revenue growth above 8% a year
  • More cash than debt, or low debt to equity
  • Positive free cash flow

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • 5-year EPS growth above 10% a year
  • 5-year average ROIC above 12%
  • Profitable 5 years in a row

Valuation

P/E (TTM)39.4
Forward P/E90.0
P/FCF25.8
P/S2.3
P/B3.1
EV/EBITDA14.3
PEG—
Dividend yield0.00%
FCF yield3.9%
Shareholder yield0.0%
Intrinsic value vs. price−65%

Growth and quality

Revenue growth (1 yr)26.6%
Revenue growth (5 yrs, per year)12.1%
EPS growth (5 yrs, per year)-40.8%
FCF growth (3 yrs, per year)36.8%
Net margin (5-yr avg.)1.4%
ROIC (5-yr avg.)3.0%
Profitable years (of last 10)5
Years paying a dividend—

Financials, last 7 years

Fiscal yearTTM2025202420232022202120202019
Revenue$387M$376M$297M$245M$206M$199M$212M$189M
Net income$24M$3M-$12M-$11M$14M$16M$38M$41M
Free cash flow$35M$54M-$3M-$19M$21M$27M$79M$72M
EPS (diluted)$0.29$0.04$-0.17$-0.15$0.19$0.23$0.53$0.57
Net margin6.3%0.8%-4.0%-4.3%6.7%8.0%17.8%21.4%
ROIC—7.4%-3.1%-2.2%8.1%4.9%35.6%45.1%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 4 analysts is $35.70, 183% above the current price; targets range from $25.80 to $41.00; the consensus rating is “Strong buy”; expected EPS is $0.26 for the fiscal year ending December 31, 2026.

Frequently asked questions

What is Pharming Group’s P/E ratio?

About 39.4, based on the last twelve months of diluted earnings per share (forward P/E about 90.0).

Is Pharming Group stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 65% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Pharming Group pay a dividend?

Not currently.

Is Pharming Group a good stock to buy?

We do not give buy or sell advice. Pharming Group scores 2.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.